X4 Pharmaceuticals (XFOR) risk factors, FY2024 10-K

Other

1. 01Summary of Selected Risks Associated with Our Business

Risks Related to Our Financial Position and Need for Additional Capital

1. 02We have incurred significant losses and have not generated significant revenue from product sales since our inception. We expect to continue to incur losses for the foreseeable future and we may never achieve or maintain profitability
2. 03Our operating plan and liquidity position will require substantial additional funding. Our history of recurring losses and
3. 04We may be forced to delay or reduce the scope of our development programs and/or limit or cease our operations if we are unable to obtain additional funding to support our current operating plan
4. 05debt facility with Hercules contains a minimum cash financial covenant. If we default on such indebtedness, with Hercules or a future lender, we could be required to pledge additional assets, or the lenders could enforce remedies on the current collateral
5. 06Changes in estimates regarding fair value of intangible assets may result in an adverse impact on our results of operations

Risks Related to Development of Our Product Candidates

1. 07We have not generated significant revenues from product sales since inception and may never become profitable. We may never be able to generate meaningful revenues from sales of XOLREMDI at levels or on timing necessary to support our investment and goals
2. 08If the commercial opportunity for mavorixafor in WHIM syndrome and other chronic neutropenic disorders is smaller than we anticipate, our potential future revenue from mavorixafor for the treatment of any of these diseases may be adversely affected and our business may suffer
3. 09We may develop mavorixafor, and potentially future product candidates, in combination with other therapies, which could expose us to additional risks
4. 10If we fail to comply with any of our obligations under the Genzyme license agreement, or we are subject to a bankruptcy, Genzyme may have the right to terminate the license agreement, in which event we would not be able to market any product candidates covered by the license
5. 11The results of clinical trials may not support our product candidate claims
6. 12Product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including marketing withdrawal
7. 13We may fail to enroll a sufficient number of patients in our clinical trials in a timely manner, which could delay or prevent clinical trials of our product candidates
8. 14Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials
9. 15Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data

Risks Related to the Marketing and Commercialization of Our Product Candidates

1. 16studies or post-market surveillance. Progress reports are required at quarterly intervals, every six months and at annual intervals depending upon the country, and more frequently if serious adverse events occur
2. 17The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability
3. 18Our commercial success depends upon attaining significant market acceptance of our approved product or product candidates, if approved, among hospitals, physicians, patients and healthcare payors
4. 19If we are unable to maintain effective sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product or product candidates, we may not be successful in commercializing our product candidates that have been approved
5. 20We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do
6. 21Even though we have obtained approval for one of our product candidates from the FDA, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and could harm our business
7. 22If we seek approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could harm our business
8. 23Any products that we commercialize may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business
9. 24country. Adverse pricing limitations may hinder our ability to recoup our investment in XOLREMDI or future product candidates, even if those candidates obtain marketing approval
10. 25Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any
11. 26Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the commercialization of any product candidates we may develop

Risks Related to Government Regulation

1. 27Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product or product candidates and affect the prices we may obtain

Risks Related to Our Dependence on Third Parties

1. 28Disruptions in our supply chain could delay the commercial sale of our product
2. 29Our employees, principal investigators, CROs, CMOs and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business
3. 30We have established, and may seek to selectively establish in the future, collaborations, and, if we are unable to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans
4. 31We may depend on such collaborations for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates

Risks Related to Our Intellectual Property

1. 32Recent laws and rulings by U.S. courts make it difficult to predict how patents will be issued or enforced in our industry
2. 33Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may have a significant impact on our ability to protect our technology and enforce our intellectual property rights
3. 34We depend on our ability to protect our proprietary technology. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection
4. 35We could be required to incur significant expenses to obtain our intellectual property rights, and we cannot ensure that we will obtain meaningful patent protection for our product candidates
5. 36Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
6. 37Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
7. 38We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful
8. 39If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business
9. 40required to cease our development and commercialization of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects
10. 41From time to time, we may need to rely on licenses to proprietary technologies, which may be difficult or expensive to obtain or we may lose certain licenses which may be difficult to replace
11. 42Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
12. 43Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
13. 44Our trade secrets are difficult to protect and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
14. 45We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
15. 46We may not be able to protect our intellectual property rights throughout the world

Risks Related to Our Business Operations, Employee Matters and Managing Growth

1. 47Our future success depends on our ability to retain executives and to attract, retain and motivate key personnel in a competitive environment for skilled biotechnology personnel
2. 48We will need to scale the size of our organization, and we may experience difficulties in managing this reduction in size
3. 49The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render our technologies and products obsolete or uncompetitive
4. 50Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations
5. 51Our term loan contains restrictions that limit our flexibility in operating our business
6. 52As noted above, the Hercules Loan Agreement also requires that we maintain a minimum level of cash of greater than 20% of our outstanding borrowings under the Hercules Loan Agreement and subject to certain operational covenants

Risks Related to Ownership of Our Common Stock

1. 53We are currently not in compliance with the Nasdaq continued listing requirements. If we are unable to regain compliance with Nasdaq’s listing requirements, our securities could be delisted, which could affect our common stock’s market price and liquidity and reduce our ability to raise capital
2. 54The notification has no immediate effect on the listing of our common stock on Nasdaq
3. 55Our stock price has been and is likely to continue to be volatile and fluctuate substantially
4. 56“Penny stock” rules may make buying or selling our securities difficult which may make our stock less liquid and make it harder for investors to buy and sell our securities
5. 57If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline
6. 58We do not anticipate that we will pay any cash dividends in the foreseeable future
7. 59Sales of a substantial number of shares of our common stock in the public market could cause our stock price to decline
8. 60consolidated financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock
9. 61We are a “smaller reporting company” and cannot predict if the reduced reporting requirements applicable to smaller reporting companies will make our securities less attractive to investors
10. 62We may become involved in securities class action litigation or shareholder derivative litigation that could divert management’s attention and harm our business and insurance coverage may not be sufficient to cover all costs and damages
11. 63Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management